Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by University of California, Los Angeles
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Marco Giovannini, M.D.,Ph.D., University of California, Los Angeles Identifier:
First received: April 21, 2011
Last updated: February 19, 2015
Last verified: February 2015

April 21, 2011
February 19, 2015
December 2012
February 2017   (final data collection date for primary outcome measure)
Vestibular schwannoma volume [ Time Frame: 1 year (12 months) ] [ Designated as safety issue: No ]
Determine the effect of RAD001 on change in vestibular schwannoma volume (mm3) by MRI from baseline to 1 year.
Same as current
Complete list of historical versions of study NCT01345136 on Archive Site
  • Hearing [ Time Frame: 1 year (12 months) ] [ Designated as safety issue: No ]
    Determine the effects of RAD001 treatment on hearing changes (from baseline to 1 year in the ear with the growing vestibular schwannoma.
  • Number of adverse events [ Time Frame: 1 year, 1 month (13 months) ] [ Designated as safety issue: Yes ]
    Determine the number of study subjects with adverse events by grade of severity
Same as current
Not Provided
Not Provided
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
A Single Arm, Monocenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma

The purpose of the study is to determine if RAD001 treatment will shrink or slow the growth of the vestibular schwannoma(s) in Neurofibromatosis 2 (NF2) patients. Secondary objectives include determining if RAD001 treatment will improve hearing ability in NF2 patients.

RAD001 is an oral drug that is approved by Food and Drug Administration (FDA) for other types of tumors, it is not approved by the FDA for treatment of NF2 related tumors.

This protocol is a Phase II, open-label, efficacy and safety study of single-agent RAD001 in patients with NF2. During the study, subjects will receive continuous daily oral treatment with RAD001 for up to 1 year or until tumor progression.

Primary Objective: To determine whether RAD001 has an effect on the VS growth in patients with NF2 at a rate sufficient to submit the drug for further testing.

Secondary Objectives: To determine whether RAD001 has an effect on the volume of other intracranial tumors, and to assess the effect of RAD001 on hearing function in patients with NF2 (when applicable).

Phase 2
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Neurofibromatosis Type 2
  • Neuroma, Acoustic
Drug: RAD001, everolimus
Adults: 10 mg p.o. daily dose, age 16 - 17: 3.0 mg/m2 p.o. daily
Other Names:
  • Everolimus
  • Afinitor
Experimental: RAD001 Treatment
All subjects will be given RAD001 for 1 year (12 months).
Intervention: Drug: RAD001, everolimus

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
February 2017
February 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of NF2 by National Institutes of Health (NIH) criteria
  • Age ≥ 16 years
  • Progressive VS growth during the previous 12 months.
  • WHO performance status > or = 2
  • Adequate bone marrow, liver and renal function.
  • For women of childbearing potential, no pregnancy or breast-feeding
  • Willingness and ability to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.
  • Willingness to provide informed consent

Exclusion Criteria:

  • Inability to tolerate periodic MRI scans or gadolinium contrast.
  • Inability to tolerate periodic audiologic testing or to understand a language with established scoring for word recognition testing.
  • Inability to adequately perform volumetric measurement of at least 1 target lesionNote: Patients with cochlear or auditory brainstem implants may participate if a target lesion can be accurately assessed.
  • Radiation therapy for the target lesion in the 60 months preceding inclusion in the study.
  • Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug.
  • Immunization with attenuated live vaccines within one week of study entry or during study period.
  • Presence of a fungal infection requiring systemic antifungal treatment at enrollment
  • Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin.
  • Patients who have any severe and/or uncontrolled medical conditions.
  • Patients with a known hypersensitivity to everolimus or other types of rapamycin or to its excipients.
  • Patients unwilling to or unable to comply with the protocol
16 Years to 65 Years
Contact: Marco Giovannini, MD, PhD
Contact: Roberta Leyvas (310) 825-8496
United States
Marco Giovannini, M.D.,Ph.D., University of California, Los Angeles
University of California, Los Angeles
Novartis Pharmaceuticals
Principal Investigator: Marco Giovannini, MD, PhD University of California, Los Angeles
University of California, Los Angeles
February 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP